NASDAQ: SPRYArs Pharmaceuticals Inc Stock
$4.11-0.04 (-0.96%)
Updated Sep 18, 2026
SPRY Price
$4.11
Fair Value Price
N/A
Market Cap
$408.73M
52 Week Low
$4.10
52 Week High
$13.15
P/E
-1.89x
P/B
32.67x
P/S
6.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$116.93M
Earnings
-$215.43M
Gross Margin
71.4%
Operating Margin
-177.88%
Profit Margin
-184.2%
Debt to Equity
18.94
Operating Cash Flow
-$196M
Beta
1.08
Next Earnings
Nov 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SPRY Overview
Silverback Therapeutics Incoporated is a clinical-stage biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. Its tissue-targeted therapeutics treat chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B. Silverback Therapeutics was incorporated in 2016 and is headquartered in Seattle, WA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPRY's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPRY
Ranked#349 of 461
Ranked#349 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.60 | A | |
| $350.84 | A | |
| $42.02 | A |
Be the first to know about important SPRY news, forecast changes, insider trades & much more!
SPRY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SPRY is poor value based on its book value relative to its share price (32.67x), compared to the US Biotechnology industry average (5.28x)
P/B vs Industry Valuation
SPRY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SPRY due diligence checks available for Premium users.
Valuation
SPRY fair value
Fair Value of SPRY stock based on Discounted Cash Flow (DCF)
Price
$4.11
Fair Value
-$5.70
Undervalued by
172.06%
SPRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPRY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.89x
Industry
9.29x
Market
44.48x
SPRY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
32.67x
Industry
5.28x
SPRY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRY's financial health
Profit margin
Revenue
$33.7M
Net Income
-$62.3M
Profit Margin
-185.2%
SPRY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SPRY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$249.5M
Liabilities
$237.0M
Debt to equity
18.94
SPRY's short-term assets ($211.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRY's short-term assets ($211.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SPRY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$60.9M
Investing
$41.6M
Financing
$3.2M
SPRY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRY vs Biotech Stocks
Ars Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.